February 14, 2012 — A jury awarded RadioMed Corp. $200,000 from ONC Solutions as compensation for ONC using confidential and proprietary information in the development of its products starting in 2007. The case included patented information used in the development of the Visicoil, a gold tumor marker used to better guide radiation therapy.
RadioMed, a subsidiary of Ion Beam Applications (IBA), said it was prepared for any extension to this case should ONC Solutions appeal the verdict.
“We are very pleased the jury recognized the importance of protecting the intellectual property associated with Visicoil”, said Chuck Lindley, RadioMed chief operating officer. “RadioMed has invested significant time and resources in developing this patented cancer treatment technology.”
RadioMed became part of IBA in 2003. Visicoil is a patented (U.S. patent 8,027,712) helically wound gold coil available in various diameters and lengths to aid in the treatment of a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast and other organs.
The clinical success of focused, dose-delivery procedures such as image guided radiation therapy (IGRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. Visicoil’s flexible coiled markers allow for accurate tumor localization, using a variety of visualization techniques. Visicoil is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future therapeutic procedures, per U.S. Food and Drug Administration (FDA) cleared 510(K).
For more information: www.visicoil.com
August 09, 2024 
